Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
INAB Catalyst Timeline
Dated clinical, regulatory and corporate events for IN8bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for IN8bio, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How INAB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-02-12 | DeltEx Drug Resistant Immunotherapy (DRI) | Phase 1/2 data readout | Phase 1/2 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INB-400 BiologicsNCT05664243 | Glioblastoma | Phase 1/2 | ACTIVE NOT_RECRUITING | 4 | Dec 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every INAB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| gamma-delta T cell therapy | newly diagnosed glioblastoma | Phase 1/2 | 2026-11-16 | median overall survival: 20.9 months; two year survival: 50%; median progression free survival: 13.0 months; standard of care median overall survival: 13.2 months; standard of care median progression free survival: 6.6 months; control group two year survival: 10%Read More | IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell TherapyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| FAIRBAIRN EMILYDirector | Disposition | -724,637 | $0.00 | 05/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INAB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in INAB for Q3 2026. | ||||
Ownership Trends
INAB Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How INAB ranks across every disease it competes in
INAB News
IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
IN8bio reported updated glioblastoma data at the SNO 2026 meeting, showing a median overall survival of 20.9 months for patients receiving repeat doses of gamma-delta T cell therapy. This is a 59% improvement over standard-of-care. Additionally, 50% of these patients survived for two years, compared to just 10% in the control group. The therapy also exhibited a favorable safety profile.
Read more →IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IN8bio, Inc. announced the grant of a nonqualified stock option for 4,000 shares to a new employee. This award, approved by the Compensation Committee, is part of the 2026 Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4). The stock option will vest over four years, promoting employee retention.
Read more →IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
IN8bio reported its third quarter 2026 financial results, highlighting the appointment of Dr. Oxana Polyakova as Senior VP of R&D. The company received recognition for INB-619 in a Nature Reviews article. They remain on track to present initial in vivo data for INB-619 by the end of 2026.
Read more →IN8bio to Present at Sidoti Small-Cap Virtual Conference
IN8bio, Inc. announced that CEO William Ho will present at the Sidoti Small-Cap Virtual Conference on September 24, 2026. The presentation will highlight the company's unique gamma-delta T cell platform and its lead program, INB-619, along with other clinical-stage initiatives. Investors can participate in one-on-one meetings during the event.
Read more →IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
IN8bio, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. CEO William Ho will lead a fireside chat and the management team will meet with investors. The event will be webcasted for broader access.
Read more →IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
IN8bio has appointed Dr. Oxana Polyakova as Senior Vice President of Research & Development. Dr. Polyakova, an expert in gamma-delta T cell biology, brings extensive experience from her previous roles in various biotech companies. Her leadership is expected to enhance IN8bio's T cell engager programs and advance their therapeutic pipeline.
Read more →IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
IN8bio reported strong second quarter results, highlighting advancements in its gamma-delta T cell engager platform and promising clinical data for its DeltEx DRI in glioblastoma patients. The median overall survival for treated patients exceeded 19.5 months, with no significant toxicities observed. The company aims to continue its progress with upcoming preclinical data and regulatory discussions.
Read more →IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
IN8bio announced the publication of clinical results demonstrating that its DeltEx DRI therapy significantly improves progression-free survival in newly diagnosed glioblastoma patients. The Phase 1 trial showed a median progression-free survival of 16.1 months for repeat-dose patients, more than double the standard of care. The therapy was well tolerated with no dose-limiting toxicities reported, highlighting its potential as a new treatment option for this aggressive cancer.
Read more →IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
IN8bio, a clinical-stage biopharmaceutical company, has announced the publication of a review article in Nature Communications, focusing on advancements in gamma-delta T cell engineering and combination therapies for cancer. The publication, authored by leading oncologists, outlines innovative strategies that could enhance anti-tumor efficacy, especially in solid tumors. In particular, the unique properties of gamma-delta T cells and their potential to improve immunotherapy approaches are underscored.
Read more →IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
IN8bio presented updated clinical data for its DeltEx DRI at the ASCO 2026 conference, showing a median overall survival exceeding 19.5 months and a median progression-free survival of 13.0 months among patients with newly diagnosed glioblastoma. This data indicates a significant advancement over the standard-of-care, which has not changed in over 20 years. The therapy was well tolerated with no notable adverse effects, suggesting a positive outlook for patients facing this aggressive cancer. These findings underscore the potential of gamma-delta T cell therapy in transforming glioblastoma treatment outcomes.
Read more →IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma
IN8bio has presented new translational data highlighting the effectiveness of its DeltEx Drug Resistant Immunotherapy (DRI) in glioblastoma at major scientific forums. The findings suggest that repeated dosing of genetically modified gamma-delta T cells can preserve immune function and improve survival outcomes in patients. Data indicates a significant increase in intratumoral CD8+ T cell density, alongside reduced immune exhaustion markers, supporting the therapy's potential in reshaping the tumor microenvironment. The research lays the groundwork for future biomarker discovery and treatment optimization.
Read more →IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
IN8bio reported its financial results for Q1 2026, highlighting advancements in its gamma-delta T cell therapies. The company has shown promising data for glioblastoma treatments and plans to engage with the FDA regarding regulatory pathways. Upcoming milestones include presentations at major conferences and further updates at their R&D Day in May.
Read more →IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
IN8bio, a clinical-stage biopharmaceutical company, is set to present new clinical data and showcase its gamma-delta T cell programs at several upcoming medical conferences. Notably, they will hold an R&D Day on May 21, 2026, where they will highlight their novel T cell engager platform and its applications for cancer therapy. Key presentations will also occur at the ASCO Annual Meeting, focusing on the clinical progress of their gamma-delta T cell therapies for glioblastoma and other indications.
Read more →IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
IN8bio reported its financial results for Q4 and full-year 2025, highlighting advancements in its gamma-delta T cell therapy programs, particularly for glioblastoma. The company announced a $40.2 million private placement to strengthen its financial position. Updated clinical data showed improved survival outcomes for patients treated with their therapies, indicating progress despite the aggressive nature of the disease.
Read more →IN8bio to Present at TD Cowen 46th Annual Health Care Conference
IN8bio, a clinical-stage biopharmaceutical company, will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO William Ho will discuss the company's recent achievements and upcoming milestones. The conference will also feature one-on-one investor meetings and will take place in Boston from March 2-4, 2026.
Read more →IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
IN8bio has promoted Kate Rochlin, Ph.D., to President and Chief Operating Officer. Dr. Rochlin, who has been with the company since 2020, will oversee operations as IN8bio advances its clinical pipeline. She has played a key role in developing the company's T cell engager platform and has extensive experience in biotechnology. Her promotion is expected to strengthen the organization further.
Read more →IN8bio to Present at Upcoming Investor and Scientific Conferences in February
IN8bio, Inc. announced its participation in two upcoming conferences in February 2026. CEO William Ho will present at the Noble Emerging Growth Virtual Equity Conference and the IO360° Conference, where he will discuss the company's unique DeltEx Drug Resistant Immunotherapy approach and results from a Phase 1/2 study in glioblastoma. Additional details will be available on their website.
Read more →